While for most cancers incidence and mortality are decreasing, those of non-Hodgkin's
lymphoma (NHL) are steadily increasing. Research to define reasons for this increase is …

Background Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not
responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an …

Immunotherapy has emerged as a powerful therapeutic approach in many areas of clinical
oncology and hematology. The approval of ipilimumab, a monoclonal antibody targeting the …

Rationale: Fibrosis is mediated partly by extracellular matrix–depositing fibroblasts in the
heart. Although these mesenchymal cells are reported to have multiple embryonic origins …

Chimeric antigen receptor (CAR) technology, and CAR-T cells in particular, have emerged
as a new and powerful tool in cancer immunotherapy since demonstrating efficacy against …

Vaccines against SARS-CoV-2 have been rapidly approved. Although pivotal studies were
conducted in healthy volunteers, little information is available on the safety and efficacy of …

Autologous hematopoietic stem cell transplantation (aHSCT) is a highly effective treatment
of multiple sclerosis (MS). It depletes autoreactive cells and subsequently renews adaptive …

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, in which
autoreactive T and B cells play important roles. Other lymphocytes such as NK cells and …

Abstract Learning Objectives After completing this course, the reader will be able to:
Describe the pathogenesis of AL amyloidosis. Identify other disorders often associated with …

Metastatic breast cancer remains a major treatment challenge. The use of high-dose
chemotherapy (HDCT) with rescue by autologous mobilized peripheral blood (MPB) is …